RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange that the Hon'ble High Court of Punjab & Haryana has orally pronounced the Order on March 9, 2015, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories Ltd. with Sun Pharmaceutical Industries Ltd. under Sections 391 to 394, Sections 78 and 100 of the Companies Act. 1956 and Section 52 of the Companies Act, 2013. Certified true copy of the Order is awaited.

Ranbaxy Laboratories Ltd had informed the Exchange that M/s Daiichi Sankyo Company, Limited ("Daiichi Sankyo") having its registered office at 3-5-1 Nihonbashi-honcho, chuo-ku, Tokyo-103-8426, Japan, had acquired 220,690,423 Equity shares constituting 52.5% of the issued, Subscribed and Fully paid - up Equity Share Capital of Ranbaxy Laboratories Limited ("the Company"). The Company has now informed the Exchange that: "Daiichi Sankyo has acquired 48,020,900 Equity Shares of the Company today (i.e. November 7, 2008) from Mr. Malvinder Mohan Singh & Mr. Shivinder Mohan Singh, including their re

Life Insurance Corporation of India has informed the Exchange that : "As per the guideline on Institutional Transactions in shares issued by Govt. of India during the year 1990, we hereby inform that Life Insurance Corporation of India has sold 25840113 equity shares face value of Rs. 5/- each of Ranbaxy Laboratories Ltd. @ Rs. 737/- per share (vide open offer)".

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on April 22, 2008 took note of following :- 1) Acquisition of 9,669,977 Equity Shares of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) constituting 14.69% of the Equity Share Capital of Orchid by Solrex Pharmaceuticals Company (Solrex), a partnership firm between Solus Pharmaceuticals Ltd. and Rexcel Pharmaceuticals Ltd., wholly owned subsidiaries of the Company and 2) Disclosures made by Solrex to the Stock Exchanges and Orchid in regard to the above.

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has acquired 758,851 shares of M/s Zenotech Laboratories Limited (Zenotech) under Open Offer made to the shareholders of Zenotech in terms of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. Disclosure in compliance of Regulation 7(1) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. Further the Company has informed the Exchange that 78,78,906 equity shares of Rs.10/- each of Zenotech acquired by the Company and put under the Escrow Account on November 08, 2007 pursuant to the S

Ranbaxy Laboratories Ltd has informed the Exchange that: "The Board of Directors at its meeting held today i.e. January 18, 2007 has approved the following : 1) Unaudited Financial Results (Provisional) for the fourth quarter and year ended December 31, 2006. 2) Appointment of Mr. Atul Sobti, Chief Operating Officer as a Whole-time Director on the Board of Company. 3) Acquisition of a strategic stake of 14.9% in Krebs Biochemicals and Industries Ltd, Hyderabad".